ProPhase Labs ( NASDAQ: PRPH ) reported that Pharmaloz Manufacturing, its wholly-owned subsidiary, is projecting significant revenues and earnings growth for the second half of 2024 and the entire year of 2025. ProPhase believes there are several strategic options for PMI in 2024 and 2025 that may provide significant liquidity and value creation for the Company, though there can be no assurance that any transaction will occur. The company believes that beginning in the current Q3 2024, PMI’s 12-month forward looking revenue run rate with one production line will be approximately $14-16 million and approximately $5 million in pre-tax net profits.
These results are anticipated solely through operation of PMI’s first enhanced manufacturing line. The company also anticipates the arrival of new manufacturing equipment for its second lozenge manufacturing line in the current fiscal quarter. Source: Press Release More on ProPhase Labs ProPhase Labs: Hidden Gem With An AI Kicker ProPhase Labs, Inc.
(PRPH) Q1 2024 Earnings Call Transcript ProPhase Labs Q1 2024 Earnings Preview Seeking Alpha’s Quant Rating on ProPhase Labs Historical earnings data for ProPhase Labs.